PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

Sponsor
Copenhagen University Hospital, Hvidovre
Study ID
NCT07263490
Status
Recruiting
Apply to this trial

Conditions

  • ART
  • Gestational Diabetes
  • Hypertensive Disorders of Pregnancy
  • Intrauterine Growth Restriction (IUGR)
  • Neonatal Morbidity
  • Neonatal Mortality
  • Oocyte Donation
  • Placental Abruption
  • Post-partum Hemorrhage (PPH)
  • Pre-Eclampsia, Severe
  • Pre-Eclampsia; Complicating Pregnancy
  • Pre-Eclampsia; Mild
  • Pre-eclampsia
  • Pre-eclampsia or Eclampsia With Pre-existing Hypertension
  • Preterm Labor

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes. Participants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.

Key Dates

First listed
Dec 4, 2025
Start date
Oct 21, 2024
Status verified
Apr 2026
Primary completion
Oct 31, 2027
Completion
Jun 1, 2028

Study Design

Enrollment
462 participants (estimated)

Arms

  • Arm: Preg OD
    Women pregnant after treatment with oocyte donation
  • Arm: Preg IVF
    Women pregnant after IVF treatment with autologous oocytes

Primary Outcome Measure

Pre-eclampsia [ Time Frame: During pregnancy and in the following two weeks post-partum ]

Related Studies